Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Psilocybin-assisted Therapy for Alcohol Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 90
- Registration Number
- NCT06444243
Open-Label Psilocybin Study in Transdiagnostic Population
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT06442423
- Locations
- 🇺🇸
Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut, United States
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 20
- Registration Number
- NCT06430541
- Locations
- 🇺🇸
Outpatient CTRC, Aurora, Colorado, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 15
- Registration Number
- NCT06416085
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of Psilocybin for PTSD
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT06407635
- Locations
- 🇺🇸
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Psilocybin Vs Ketamine for Alcohol Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 80
- Registration Number
- NCT06405607
Study of Psilocybin for Anorexia in Young Adults
- Conditions
- Interventions
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Marissa Raymond-Flesch, MD, MPH
- Target Recruit Count
- 40
- Registration Number
- NCT06399263
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 15
- Registration Number
- NCT06386003
- Locations
- 🇨🇦
St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
Psilocybin for Hospitalized Patients With Treatment-resistant Depression
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 100
- Registration Number
- NCT06378229
- Locations
- 🇧🇪
Ghent University Hospital, Gent, Oost-Vlaanderen, Belgium
Low-Income Group Psilocybin Assisted Therapy for Depression
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Matthew Hicks
- Target Recruit Count
- 24
- Registration Number
- NCT06372197
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.